Mani, Inc (MNICF) Fair Value & Analysis
Healthcare · US · Market cap $1.3B
Mani, Inc
MNICF · US
Fair value as of: Jul 18, 2026
From 24 valuation models · updated 23 days ago
Fair value updated Jul 18, 2026, revised from $5.88 to $5.84 (−0.7%) since Jun 24, 2026.
A solid business, but screening 54% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case ($7.31). The favourable scenario is already priced in.
- Solid but not exceptional quality (64/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range ($3.48 to $7.31) leaves room in how you read the outcome.
Price vs Fair Value (22 months)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 18, 2026.
How to read this chart
22‑month range $12.21 – $12.82 · fair‑value band $3.48 – $7.31 · the $12.82 price screens above the $5.84 fair value. Dashed = 300-day average. As of Jul 18, 2026.
Analysis
Mani, Inc (MNICF) currently trades at $12.82, while our model-based Fair Value estimate is $5.84, implying the stock looks roughly 54.5% overvalued today. The Quality Score stands at 64/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Mani, Inc generated revenue of $31.3B at a net margin of 17.9%. Revenue grew 15.7% year over year. It earns a return on equity of 10.2%. The stock trades on a trailing P/E of 30.5. Fundamentals as of Jul 18, 2026
Our scenario range runs from $3.48 (bear case) to $7.31 (bull case); at $12.82, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 3% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -54%, MNICF screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Growth Earnings ($6.03) versus Growth DCF ($1.56). Highest evidence: Growth DCF (72).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 18, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 62 · Market factors (momentum, volatility) 66
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Mani, Inc. engages in the manufacture and supply of surgical and dental instruments in Japan, Asia, Europe, North America, and internationally. The company operates through three segments: Surgical Products, Eyeless Needle Products, and Dental Products.
Full company description
Mani, Inc. engages in the manufacture and supply of surgical and dental instruments in Japan, Asia, Europe, North America, and internationally. The company operates through three segments: Surgical Products, Eyeless Needle Products, and Dental Products. The company offers surgical instruments, such as maniplers, vessel knives, ENT knives, and stainless wire needles; and ophthalmic instruments, including ophthalmic sutures and knives, and trocar kits for vitrectomy. It also provides surgical eyeless, eyed, taper point, cutting, ophthalmic needles; and dental instruments, such as endodontic instruments, endodontic rotary instruments, root canal obturation, diamond and carbide burs, finishing and polishing instruments, sutures and surgical needles, endodontic micro-accessories, and endodontic accessories. Mani, Inc. was founded in 1956 and is headquartered in Utsunomiya, Japan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Mani, Inc reported revenue of $30.0B in FY2025 versus $17.2B in FY2021, a compound +14.9%/yr. Reported net income was $4.6B in FY2025, compounding +2.0%/yr from FY2021.
MNICF screens 54% overvalued. Compare with Intuitive Surgical, Inc →
Peer Group
Medical Instruments & Supplies · 203 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 18, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.33 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €172.45 | €68.55 | -60% |
| Medline Inc MDLN | $41.11 | $30.15 | -27% |
| Becton, Dickinson and Company BDX | $150.65 | $103.53 | -31% |
| Alcon Inc ALC | $70.26 | $39.78 | -43% |
| ResMed Inc RMD | $203.87 | $187.89 | -8% |
| West Pharmaceutical Services, Inc WST | $353.71 | $143.97 | -59% |
| Straumann Holding STMN | CHF 106.00 | CHF 47.31 | -55% |
| Sartorius Stedim Biotech S.A DIM | €188.50 | €51.16 | -73% |
| Coloplast A/S COLOB | kr 414.00 | kr 382.22 | -8% |
Compare Mani, Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Mani, Inc (MNICF) overvalued or undervalued?
What is the fair value of MNICF?
What is the quality score of MNICF?
What is the revenue of Mani, Inc (MNICF)?
What is the net profit margin of MNICF?
Does Mani, Inc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Mani, Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.